News

In an interview with Targeted Oncology, Yuri E. Nikiforov, MD, PhD, discussed what led to the reclassification of NIFTP and the incidence of thyroid cancer in patients.

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

Carolyn Owen, MD, discusses data from the phase 3 GLOW study which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.

The newly approved supplemental new drug application for Illuccix by the FDA will enable patients with prostate cancer to be identified and selected for radioligand therapy.

Investigators from the China ARCHES trial of enzalutamide plus androgen deprivation therapy announced that it had met its primary end point in Chinese patients with metastatic hormone-sensitive prostate cancer.

Preclinical and phase 1/2a data evaluating the safety and tolerability of EP0042 in patients with relapsed or refractory acute myeloid leukemia has led the FDA to grant an orphan drug designation to the agent.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.

Results were published from a phase 1b trial of patients with higher-risk myelodysplastic syndromes, showing strong efficacy and safety outcomes.

Ripretinib now has 2 breakthrough therapy designations from the FDA and has been added to the NCCN guidelines for gastrointestinal stromal tumor.

Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.

As a result of the FDA’s clinical hold on the phase 1 trial, no patients with HER2-positive recurrent or metastatic solid tumors will be enrolled or dosed with XMT-2056.

Vorasidenib may break a 20-year gap in treatment advances for IDH-mutant low-grade glioma, according to phase 3 findings from the INDIGO study.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Finn, MD, discussed how treatment options for patients with hepatocellular carcinoma have advanced in recent years.

CYAD-01, an autologous CAR T-cell therapy, was tolerable and showed activity in patients with acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma.

The phase 2/3 KEYNOTE-483 trial of pembrolizumab plus chemotherapy for patients with mesothelioma elicited improvements in overall survival and showed consistent safety with previously reported data.

Gene G. Finley, MD, discusses some of the treatment options that have been used in the small cell lung cancer space, including intensive chemotherapies and targeted agents.

A phase 1b/2a trial is investigating the combination of bemcentinib with pembrolizumab and doublet chemotherapy in patients with first-line non–small cell lung cancer that harbors STK11 mutations.

A comprehensive analytical data package and pharmacokinetic, pharmacodynamic, and immunogenicity study has led the FDA to approve the pegfilgrastim biosimilar pegfilgrastim-cbqv for patients with cancer.

Soligenix has requested a Type A meeting with the FDA to get clarity around the item needed to complete the new drug application of SGX301 for patients with early-stage cutaneous T-cell lymphoma.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Findings from the patient-reported outcomes analysis of the phase 3 KEYNOTE-826 trial support the benefit of pembrolizumab in patients with recurrent, persistent, or metastatic cervical cancer.

In a vote of 11 to 2, the FDA's Oncologic Drugs Advisory Committee voted for the benefit/risk profile of polatuzumab vedotin in combination with R-CHP, based on findings from the confirmatory POLARIX trial.

Following positive phase 1 results in patients with previously treated advanced urothelial carcinoma, the FDA granted Fast Track Designation for the novel AHR inhibitor IK-175.

Alexander Spira, MD, PhD, FACP, discusses the combination of amivantamab-vmjw and lazertinib for patients with relapsed or refractory EGFR-mutant non–small cell lung cancer and findings presented at the 2022 IASLC World Conference on Lung Cancer.

Delivering cancer care from the first diagnosis is a team approach. Each step affects downstream processes.

Pixatimod and nivolumab showed benefits for patients with microsatellite-stable metastatic colorectal cancer.

The FDA has granted the cell therapy temferon an orphan drug designation to treat patients with brain cancer.

Findings from a phase 3 clinical trial, including data from high-risk children given remestemcel-L, led the FDA to accept the biologics license application of the therapy.

Neoadjuvant chemotherapy with carboplatin has been shown to improve the pathologic complete response rate for patients with triple negative breast cancer.